Do triglycerides provide meaningful information about heart disease risk?

Archives of Internal Medicine

Volumn 160, Issue 13, 2000, Pages 1937-1944

  Avins, Andrew L ^a,b   Neuhaus, John M ^b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; DIAGNOSTIC VALUE; HEART DISEASE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034632092     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.13.1937     Document Type: Article

References (46)

1. Castelli W. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol. 1992;70:3H-9H.
2. Criqui MH, Heiss G, Cohn R, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993;328:1220-1225.
3. Cambien F, Jacqueson A, Richard J, Warnet J, Ducimetiere P, Claude J. Is the level of serum triglyceride a significant predictor of coronary death in "normocholesterolemic" subjects? the Paris Prospective Study. Am J Epidemiol. 1986; 124:624-632.
4. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733-737.
5. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992; 85:37-45.
6. Gotto AM. Triglyceride: the forgotten risk factor. Circulation. 1998;97:1027-1028.
7. Ginsberg HN. Is hypertriglyceridemia a risk factor for atherosclerotic disease? a simple question with a complicated answer. Ann Intern Med. 1997;126:912-914.
8. NIH Consensus Conference. Triglyceride, high-density lipoprotein, and coronary heart disease: NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. JAMA. 1993;269:505-510.
9. Gotto AM Jr. Hypertriglyceridemia: risks and perspectives. Am J Cardiol. 1992; 70:19H-25H
10. Patsch W, Gotto AM Jr. High-density lipoprotein cholesterol, plasma triglyceride, and coronary heart disease: pathophysiology and management. Adv Pharmacol. 1995;32:375-426.
11. Grundy SM. Consensus statement: role of therapy with "statins" in patients with hypertriglyceridemia. Am J Cardiol. 1998;81:1B-6B.
12. Kesaniemi YA. Serum triglycerides and clinical benefit in lipid-lowering trials. Am J Cardiol. 1998;81:70B-73B.
13. Davignon J, Cohn JS. Triglycerides: a risk factor for coronary heart disease. Atherosclerosis. 1996;124(suppl):S57-S64.
14. Havel RJ, Rapaport E. Management of primary hyperlipidemia. N Engl J Med. 1995;332:1491-1498.
15. Superko HR. Beyond LDL cholesterol reduction. Circulation. 1996;94:2351-2354.
16. Avins AL, Hulley SB. Joint effects of serum triglycerides and LDL and HDL cholesterol. Circulation. 1993;87:300-301.
17. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992;116:78-84.
18. Austin MA. Joint lipid risk factors and coronary heart disease. Circulation. 1992; 85:365-367.
19. Sherwin R, Kaelber CT, Kezdi P, Kjelsberg MO, Thomas HE Jr. The Multiple Risk Factor Intervention Trial (MRFIT), II: the development of the protocol. Prev Med. 1981;10:402-425.
20. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA. 1982;248: 1465-1477.
21. The Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
22. The Lipid Research Clinics Program. The Coronary Primary Prevention Trial: design and implementation. J Chronic Dis. 1979;32:609-631.
23. The Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation. 1979;60:427-439.
24. Williams OD, Stinnett S, Chambless LE, et al. Populations and methods for assessing dyslipoproteinemia and its correlates: the Lipid Research Clinics Program Prevalence Study. Circulation. 1986;73(suppl I):I4-I11.
25. Multiple Risk Factor Intervention Trial Research Group. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Prev Med. 1986;15:254-273.
26. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43-46.
27. StataCorporation Stata Statistical Software [computer program]. Version 5.0. College Station, Tex: Stata Corp; 1997.
28. Parmar MKB, Machin D. Survival Analysis: A Practical Approach. New York, NY: John Wiley & Sons Inc; 1995.
29. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1998.
30. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561-577.
31. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
32. Mossman D. Resampling techniques in the analysis of non-binormal ROC data. Med Decis Making. 1995;15:358-366.
33. Adult Treatment Panel II. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 1993;269:3015-3023.
34. Avins AL, Haber RJ, Hulley SB. The status of hypertriglyceridemia as a risk factor for coronary heart disease. Clin Lab Med. 1989;9:153-168.
35. Pocock SJ, Shaper AG, Phillips AN. Concentrations of high-density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. BMJ. 1989;298:998-1002.
36. Freedman DS, Gruchow HW, Anderson AJ, Rimm AA, Barboriak JJ. Relation of triglyceride levels to coronary artery disease: the Milwaukee Cardiovascular Data Registry. Am J Epidemiol. 1988;127:1118-1130.
37. Austin MA. Plasma triglycerides and coronary heart disease. Arterioscler Thromb Vasc Biol. 1991;11:2-14.
38. Garber AM, Avins AL. Triglyceride concentration and coronary heart disease. BMJ. 1995;310:259-260.
39. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3: 213-219.
40. Levy R, Brensike J, Epstein S, et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984; 69:325-337.
41. The Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
42. Canner P, Berge K, Wenger N, et al. Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
43. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260: 641-651.
44. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97:1453-1460.
45. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440-1445.
46. Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation. 1998;97:1446-1452.